The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Diabetic Retinopathy: Pathophysiology and Treatments
Open accessAbstract
Diabetic retinopathy (DR) is the most common complication of diabetes mellitus (DM). It has long been recognized as a microvascular disease. The diagnosis of DR relies on the detection of microvascular lesions. The treatment of DR remains challenging. The advent of anti-vascular endothelial growth factor (VEGF) therapy demonstrated remarkable clinical benefits in DR patients; however, the majority of patients failed to achieve clinically-significant visual improvement. Therefore, there is an urgent need for the development of new treatments. Laboratory and clinical evidence showed that in addition to microvascular changes, inflammation and retinal neurodegeneration may contribute to diabetic retinal damage in the early stages of DR. Further investigation of the underlying molecular mechanisms may provide targets for the development of new early interventions. Here, we present a review of the current understanding and new insights into pathophysiology in DR, as well as clinical treatments for DR patients. Recent laboratory findings and related clinical trials are also reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,428
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Adamis, A. P., Miller, J. W., Bernal, M.-T., D'Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,296
Barber, A. J., Lieth, E., Khin, S. A., Antonetti, D. A., Buchanan, A. G., & Gardner, T. W. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2425 · Cited by 1,295
A central role for inflammation in the pathogenesis of diabetic retinopathy
Joussen, A. M., Poulaki, V., Le, M. L., Koizumi, K., Esser, C., Janicki, H., Schraermeyer, U., Kociok, N., Fauser, S., Kirchhof, B., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-1476fje · Cited by 1,176
Boyer, D. S., Yoon, Y. H., Belfort, R., Bandello, F., Maturi, R. K., Augustin, A. J., Li, X.-Y., Cui, H., Hashad, Y., & Whitcup, S. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.024 · Cited by 1,122
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Bressler, N. M., Bressler, S. B., Brucker, A. J., Ferris, F. L., Hampton, G. R., Jhaveri, C., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.022 · Cited by 1,051
Research works printed but not linked: 10
- Lupo, 2013, Role of phospholipases A2 in diabetic retinopathy: In vitro and in vivo studies, Biochem. Pharmacol., 86, 1603, 10.1016/j.bcp.2013.09.008 · doi:10.1016/j.bcp.2013.09.008
- Kasza, 2017, Plasma E-selectin levels can play a role in the development of diabetic retinopathy, Graefe’s Arch. Clin. Exp. Ophthalmol., 255, 25, 10.1007/s00417-016-3411-1 · doi:10.1007/s00417-016-3411-1
- Limb, 1999, Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy, Investig. Ophthalmol. Vis. Sci., 40, 2453
- Sivkova, 2011, Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy, Folia Med., 53, 44
- Abcouwer, 2017, Muller cell-microglia cross talk drives neuroinflammation in diabetic retinopathy, Diabetes, 66, 261, 10.2337/dbi16-0047 · doi:10.2337/dbi16-0047
- Wroblewski, 2016, Topical squalamine 0.2% and intravitreal ranibizumab 0.5 mg as combination therapy for macular edema due to branch and central retinal vein occlusion: An open-label, randomized study, Ophthalmic Surg. Lasers Imag. Retina, 47, 914, 10.3928/23258160-20161004-04 · doi:10.3928/23258160-20161004-04
- Pacella, 2016, Management of anterior chamber dislocation of a dexamethasone intravitreal implant: A case report, J. Med. Case Rep., 10, 282, 10.1186/s13256-016-1077-2 · doi:10.1186/s13256-016-1077-2
- Arnarsson, 2000, Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion, Investig. Ophthalmol. Vis. Sci., 41, 877
- Ogata, 2001, Upregulation of pigment epithelium-derived factor after laser photocoagulation, Am. J. Ophthalmol., 132, 427, 10.1016/S0002-9394(01)01021-2 · doi:10.1016/s0002-9394(01)01021-2
- Vujosevic, 2013, Subthreshold laser therapy for diabetic macular edema: Metabolic and safety issues, Curr. Med. Chem., 20, 3267, 10.2174/09298673113209990030 · doi:10.2174/09298673113209990030
Cited by
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Self-citationMechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy
Yang, J., & Liu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816400 · Cited by 281
Xu, G.-T., Zhang, J.-F., & Tang, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.355743 · Cited by 280
Experimental animal models for diabetes and its related complications—a review
Kottaisamy, C. P. D., Raj, D. S., Prasanth Kumar, V., & Sankaran, U. (2021) · Laboratory Animal Research · doi:10.1186/s42826-021-00101-4 · Cited by 263
Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy
Rudraraju, M., Narayanan, S. P., & Somanath, P. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105115 · Cited by 217
The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Gelfman, C. M., Grishanin, R., Bender, K. O., Nguyen, A., Greengard, J., Sharma, P., Nieves, J., Kiss, S., & Gasmi, M. (2021) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2021.0001 · Cited by 55
“DME is a complication of diabetic retinopathy (DR), a leading cause of visual loss in the working-age population.(1) Three recombinant anti-VEGFA proteins (ranibizumab, bevacizumab, and aflibercept), all of which are administered through IVT injection every 4 to 8 weeks, are typically the first line of treatment for b…”
BackgroundShi, J., Lv, H., Tang, C., Li, Y., Huang, J., & Zhang, H. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12112 · Cited by 34
Animal models for induction of diabetes and its complications
Qamar, F., Sultana, S., & Sharma, M. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01277-3 · Cited by 24
“According to this model, the disease begins 12 weeks after hyperglycaemia and is signalled by reactive gliosis and an increase in retinal vascular permeability [60].”
MethodWewetzer, L., Held, L. A., Goetz, K., & Steinhäuser, J. (2023) · DIGITAL HEALTH · doi:10.1177/20552076231176644 · Cited by 23
Ahmed, A., Sattar, N., & Yaghootkar, H. (2022) · Diabetic Medicine · doi:10.1111/dme.14982 · Cited by 10
Diaz, E. A., Seifert, M. L., Gruning, V., Stadnick, N. A., Lugo-Butler, E., Servin, A. N., Rodríguez-Rosales, C. I., Geremia, C., Ramachandra, C., Bhaskaranand, M., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.38114 · Cited by 9
Xie, X., Wu, C., Huang, Z., Zhou, Y., Huang, J., Dao, F., Yan, D., Deng, K., Lyu, H., Ma, C., et al. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag083 · Cited by 9
“Current clinical diagnosis primarily relies on retinal vascular changes [37], while the rapid advancement of AI is driving new auxiliary diagnostic solutions (Fig.”
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
“Inflammation is involved in the pathophysiology of DR as well (Wang and Lo, 2018).”
Ansari, P., Khan, J. T., Choudhary, S., Reberio, A. D., Kumar, S., Seidel, V., Abdel-Wahab, Y. H. A., & Flatt, P. R. (2024) · doi:10.20944/preprints202408.1739.v1 · Cited by 89
Metadata
- Authors
- Wang, W., & Lo, A. C. Y.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-06-20
- Volume
- 19
- Issue
- 6
- Pages
- 1816
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2809489644
- Cited by
- 1,358
- References
- 69
- FWCI
- 64.51
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Health and Medical Research Fund (04150746)
- The University of Hong Kong Seed Funding Programme for Basic Research (201310159038)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.